Viberzi denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Viberzi as Not Medically Necessary

A medical-necessity denial for Viberzi (eluxadoline) typically means Cigna's clinical reviewers determined the drug was not justified under its coverage criteria for irritable bowel syndrome with diarrhea (IBS-D) — most often because the submission lacked sufficient documentation of diagnosis, symptom severity, or prior treatment failures. Medical-necessity denials are among the most commonly overturned on appeal when complete clinical documentation is submitted.

## Why This Denial Is Appealable

Cigna's coverage criteria for Viberzi are generally aligned with its FDA-approved indication. If your prescriber can document that you have confirmed IBS-D, that your symptoms are clinically significant, and that you have tried and had inadequate responses to appropriate prior therapies, you have a strong factual basis for appeal. The key is translating your clinical story into the specific language of Cigna's coverage policy.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered plans must offer an internal appeal and, if denied, access to independent external review by an accredited IRO. Under ERISA §503, self-funded employer plans owe you a full-and-fair review with written explanation of any adverse decision. The external-review request window is generally approximately four months from the denial notice. Request expedited review if your condition is urgent.

## The Appeal Process

1. Request the denial details. Ask for the specific coverage policy and the clinical criteria Cigna applied. Note every unmet criterion listed. 2. Level 1 internal appeal. Submit within the deadline in your denial letter. Include the full documentation package described below. 3. Level 2 / external review. If the internal appeal is denied, escalate to external review immediately. An IRO's independent determination carries significant weight.

## Documentation to Gather

• Diagnosis confirmation: Chart notes, symptom history, and any relevant diagnostic workup establishing IBS-D.
• Symptom severity documentation: Recent visit notes quantifying stool frequency, urgency, pain scores, and functional impairment.
• Prior treatment history with outcomes: A chronological list of each prior IBS-D therapy — including dates started, dates stopped, doses, and specific reasons for discontinuation or inadequate response.
• Prescriber medical-necessity letter: A detailed letter from your gastroenterologist or treating physician addressing each criterion in Cigna's policy point by point.
• Relevant guidelines: Reference the applicable gastroenterology society guideline organization's recommendations for IBS-D management to contextualize the treatment choice.

## Criteria-Mapping Structure

Obtain Cigna's current medical coverage policy for eluxadoline/Viberzi and list each requirement. For every requirement, record the specific chart fact that satisfies it — for example, matching each step-therapy requirement to a documented trial with outcome. Confirm exact eligibility thresholds by consulting both the FDA-approved prescribing label and Cigna's published policy; do not rely on third-party summaries, as criteria can change.